|
March 12, 2003
The 2002 BioIndustry Review,
which chronicles key events and trends in the biotech industry
in both Australia and New Zealand, has been released at a
BioBusiness Forum in Sydney.
The Review, written by key industry commentators Dr Kelvin
Hopper and Dr Lyndal Thorburn, reviews the events of 2002 and
predicts major issues that need to be addressed by the industry
in the coming
twelve months.
This report is the second in their annual series, and covers key
events for 2002, with financial information spanning 2001/02.
Author Dr Kelvin Hopper, of
Aoris Nova in Sydney, says that “the BioIndustry Review is
the only source of authoritative information on small, private
biotech firms, which comprise 80% of the industry in Australia
and about 50% in New Zealand. It is an important source of
information for government agencies forming policies to support
this industry. It also provides good benchmarking information
for research institutions, firms and investors.”
Second author Dr Lyndal Thorburn, of
Advance
Consulting & Evaluation, in Canberra, stated that “New
Zealand has been included in this edition because interest in
biotech has picked up there since the conclusion of the Royal
Commission on Genetic Modification. A higher proportion of New
Zealand’s biotech firms have products on the market (when
compared to Australia), and the government is moving forward
rapidly on a range of fronts. This report is the first time that
definitive information has been compiled on industry strengths
and trends in that country.
Dr Hopper adds that, as well as surveying biotech firms in both
countries, the report draws on a specific survey of the service
sector, which plays a crucial role in supporting the biotech
industry at
this stage of its development, but one often overlooked in
government policy.
“Overall, we are optimistic about the prospects for the
industry,” Dr Hopper said. “However, we need to build company
size and international growth to be able to compete effectively
and we see bigger opportunities for devices and diagnostics,
having a lower risk profile compared to many of the health and
therapeutic technologies, which are emerging from our research
institutions.”
|
2002
BioIndustry Review
- Australia & New Zealand
What
have been the key trends in Australia's and New Zealand's
bio-industries and what is the outlook for 2003?
Find out in Australia and New Zealand's
definitive BioIndustry publication.
Written by two key industry advisors, Dr
Kelvin Hopper and
Dr. Lyndal Thorburn, the
report is based on specific surveys and analysis, and is
an authoritative review and critique of important
developments in the industry for the year passed and the
authors views on the year ahead.
In this edition of the Australian & NZ
Bioindustry Review you will find:
-
Focus on the activities of both unlisted
and listed companies;
-
National industry overview and key
trends for 2002;
-
Summary of major company and government
events;
-
Key funding and VC trends;
-
Who formed alliances with whom;
-
Who was awarded significant US patents;
-
Table of key new startups for 2001/02;
-
Federal and State Government activity
and funding
-
Results and analysis of a major survey
of the biotech services sector; and
-
Analysis of biotechnology industry and
funding trends in New Zealand.
|
The report can be purchased for $154 from either
Aoris Nova or
Advance
Consulting & Evaluation.
For more information contact:
Dr Kelvin Hopper +61 (02) 9209 4234 - Aoris Nova
Dr Lyndal Thorburn +61 (02) 6295 6220 - Advance Consulting &
Evaluation
|
